MedTrace Logo

Study of Dehydroepiandrosterone Treatment for Poor Responders in In Vitro Fertilization Patients

NCT01535872 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-08-07

No results posted yet for this study

Summary

The aim of this study is to show solid evidences of the efficacy of DHEA in improving the success rates of in-vitro fertilization (IVF) patients facing poor ovarian reserve.

Conditions

Interventions

DIETARY_SUPPLEMENT

Dehydroepiandrosterone

DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.

Sponsors & Collaborators

  • KK Women's and Children's Hospital

    lead OTHER_GOV

Principal Investigators

  • Veronique Viardot-Foucault, MD, FAMS (Endocrinology) · KK Women's and Children's Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-10-31
Completion
2017-11-30

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01535872 on ClinicalTrials.gov